Cleerly is a healthcare company founded in 2017 that applies deep learning to cardiac computed tomography scans to characterise coronary plaque. Its analysis quantifies the amount and type of atherosclerosis rather than relying on narrowing alone, giving cardiologists a direct picture of disease burden. The technology has United States regulatory clearances and is used across hospital cardiology programmes.
James Earls · Executive Officer · decision-maker
Jim Hartman · Executive Officer · decision-maker
Nick Nieslanik · Executive Officer · decision-maker
Kristin Binns · Executive Officer · decision-maker
Careers mailbox is known
Sep 29
Hiring 4 new roles, 3 closed in 14 days
Sep 4
First executive search Regional Sales Director (Denver/Seattle)
Dec 3, 2024
Raised a round Series C $106M · led by Insight Partners
Oct 18, 2021
New executive Cleerly Appoints Jim Hartman as Chief Revenue Officer · businesswire.com
2016
Founded
20 open
+1 this week
$190k stated pay, 20 roles
truth B 81 75% stale
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
No named decision-maker yet.
Careers mailbox is known
Sep 29
Posted a role Scientist, DMPK (BioAnalytical and Medical Writing)
Sep 26
Posted 6 roles Research Investigator, Computational Chemistry, Principal Scientist, Computational Chemistry
7 open
+1 this week
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Richard Motschwiller · Executive Officer · decision-maker
John Martin · Executive Officer, Director · decision-maker
David de Graaf · Executive Officer, Director · decision-maker
Evan Thompson · Executive Officer · decision-maker
No careers mailbox known
2025
Team of 55 was 40 · US Form 5500 (plan participants)
Feb 7, 2025
Raised a round Venture round $80M · SEC Form D
2015
Founded
The BrightInsight Platform is the leading global platform for biopharma and medtech regulated digital health solutions.
Ferry Tamtoro · Executive Officer · decision-maker
Bob Michitarian · Executive Officer · decision-maker
Kal Patel · Executive Officer, Director · decision-maker
Dan Goldsmith · Director
No careers mailbox known
Sep 9
Partnership BrightInsight and Headspace Partner to Pair Mental Health Support with Treatment Adherence · The Manila Times
Jul 25, 2022
Launched BrightInsight Launches Digital Connected Diagnostics Platform at AACC in Chicago Newswise · newswise.com
Mar 10, 2021
Raised a round Venture round $101M · SEC Form D
2018
Founded
